ProQR Therapeutics Future Growth
Future criteria checks 1/6
ProQR Therapeutics's earnings are forecast to decline at 4.6% per annum while its annual revenue is expected to grow at 12.6% per year. EPS is expected to grow by 0.8% per annum. Return on equity is forecast to be -115.2% in 3 years.
Key information
-4.6%
Earnings growth rate
0.8%
EPS growth rate
Biotechs earnings growth | 28.5% |
Revenue growth rate | 12.6% |
Future return on equity | -115.2% |
Analyst coverage | Good |
Last updated | 27 Aug 2024 |
Recent future growth updates
Recent updates
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01ProQR reports Q3 results
Nov 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 12 | -43 | -52 | -67 | 4 |
12/31/2025 | 15 | -29 | -18 | -32 | 6 |
12/31/2024 | 24 | -26 | N/A | -29 | 6 |
6/30/2024 | 16 | -22 | -28 | -34 | N/A |
3/31/2024 | 11 | -27 | -32 | -38 | N/A |
12/31/2023 | 7 | -28 | 28 | 22 | N/A |
9/30/2023 | 5 | -37 | 8 | 9 | N/A |
6/30/2023 | 4 | -54 | 1 | 1 | N/A |
3/31/2023 | 4 | -59 | -4 | -3 | N/A |
12/31/2022 | 4 | -64 | -69 | -69 | N/A |
9/30/2022 | 4 | -69 | -48 | -47 | N/A |
6/30/2022 | 4 | -61 | -40 | -40 | N/A |
3/31/2022 | 3 | -63 | -35 | -35 | N/A |
12/31/2021 | 2 | -61 | -26 | -26 | N/A |
9/30/2021 | 2 | -57 | -42 | -42 | N/A |
6/30/2021 | 2 | -55 | -44 | -43 | N/A |
3/31/2021 | 1 | -43 | -45 | -44 | N/A |
12/31/2020 | 1 | -47 | -48 | -47 | N/A |
9/30/2020 | 1 | -52 | -48 | -47 | N/A |
6/30/2020 | 1 | -51 | -47 | -46 | N/A |
3/31/2020 | 2 | -58 | -47 | -47 | N/A |
12/31/2019 | 2 | -56 | -45 | -44 | N/A |
9/30/2019 | 3 | -51 | -41 | -41 | N/A |
6/30/2019 | 5 | -45 | -37 | -37 | N/A |
3/31/2019 | 6 | -40 | -32 | -31 | N/A |
12/31/2018 | 6 | -37 | -29 | -28 | N/A |
9/30/2018 | 4 | -35 | -28 | -28 | N/A |
6/30/2018 | 2 | -40 | -32 | -31 | N/A |
3/31/2018 | 1 | -44 | N/A | -36 | N/A |
12/31/2017 | 1 | -44 | N/A | -35 | N/A |
9/30/2017 | 1 | -41 | N/A | -34 | N/A |
6/30/2017 | 1 | -41 | N/A | -37 | N/A |
3/31/2017 | 1 | -39 | N/A | -35 | N/A |
12/31/2016 | 2 | -39 | N/A | -34 | N/A |
9/30/2016 | 3 | -36 | N/A | -34 | N/A |
6/30/2016 | 3 | -33 | N/A | -29 | N/A |
3/31/2016 | 3 | -31 | N/A | -27 | N/A |
12/31/2015 | 3 | -21 | N/A | -24 | N/A |
9/30/2015 | 3 | -17 | N/A | -22 | N/A |
6/30/2015 | 1 | -14 | N/A | -20 | N/A |
3/31/2015 | 1 | -10 | N/A | -18 | N/A |
12/31/2014 | 0 | -12 | N/A | -14 | N/A |
9/30/2014 | 0 | -12 | N/A | -10 | N/A |
6/30/2014 | 0 | -9 | N/A | -7 | N/A |
3/31/2014 | 0 | -5 | N/A | -4 | N/A |
12/31/2013 | 0 | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRQR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRQR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRQR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRQR's revenue (12.6% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: PRQR's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRQR is forecast to be unprofitable in 3 years.